Gempharmatech Co. Ltd. A (688046) - Total Assets
Based on the latest financial reports, Gempharmatech Co. Ltd. A (688046) holds total assets worth CN¥2.80 Billion CNY (≈ $409.51 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gempharmatech Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how Gempharmatech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Also see 688046 company net worth for the company's overall valuation and market capitalisation.
Gempharmatech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Gempharmatech Co. Ltd. A's total assets of CN¥2.80 Billion consist of 66.5% current assets and 33.5% non-current assets. Review Gempharmatech Co. Ltd. A balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 27.3% |
| Accounts Receivable | CN¥350.81 Million | 13.6% |
| Inventory | CN¥54.20 Million | 2.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥55.40 Million | 2.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Gempharmatech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Gempharmatech Co. Ltd. A for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gempharmatech Co. Ltd. A's current assets represent 66.5% of total assets in 2024, a decrease from 84.8% in 2019.
- Cash Position: Cash and equivalents constituted 27.3% of total assets in 2024, down from 57.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 5.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 13.6% of total assets.
Gempharmatech Co. Ltd. A Competitors by Total Assets
Key competitors of Gempharmatech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
USA | $511.25 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
Gempharmatech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.28 | 4.09 | 4.04 |
| Quick Ratio | 3.16 | 3.96 | 3.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.24 Billion | CN¥1.32 Billion | CN¥505.84 Million |
Gempharmatech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Gempharmatech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.17 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | CN¥2.57 Billion |
| Market Capitalization | $2.12 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Gempharmatech Co. Ltd. A's assets close to their book value (0.82x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: Gempharmatech Co. Ltd. A's assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Gempharmatech Co. Ltd. A (2019–2024)
The table below shows the annual total assets of Gempharmatech Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.57 Billion ≈ $376.46 Million |
-0.19% |
| 2023-12-31 | CN¥2.58 Billion ≈ $377.18 Million |
+14.37% |
| 2022-12-31 | CN¥2.25 Billion ≈ $329.79 Million |
+113.74% |
| 2021-12-31 | CN¥1.05 Billion ≈ $154.29 Million |
+19.39% |
| 2020-12-31 | CN¥883.19 Million ≈ $129.24 Million |
+127.55% |
| 2019-12-31 | CN¥388.14 Million ≈ $56.80 Million |
-- |
About Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides cust… Read more